首页> 美国卫生研究院文献>The Oncologist >Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer
【2h】

Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer

机译:晚期卵巢癌:原发性或间隔性减灭?从随机试验和肿瘤生物学的结果来看五类患者是晚期卵巢癌的原发减瘤术和间隔减瘤术

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background.Standard treatment of stage III and IV advanced ovarian cancer (AOC) consists of primary debulking surgery (PDS) followed by chemotherapy. Since the publication of the European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada trial, clinical practice has changed and many AOC patients are now treated with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). The best option remains unclear. Ovarian cancer is a heterogenic disease. Should we use the diversity in biology of the tumor and patterns of tumor localization to better stratify patients between both approaches?
机译:背景:III期和IV期晚期卵巢癌(AOC)的标准治疗包括初级减体手术(PDS)和化学疗法。自欧洲癌症研究与治疗组织/加拿大国家癌症研究所发表试验结果以来,临床实践发生了变化,许多AOC患者现在接受了新辅助化疗(NACT)和间隔减瘤术(IDS)的治疗。最佳选择仍然不清楚。卵巢癌是一种异源性疾病。我们是否应该利用肿瘤生物学的多样性和肿瘤的定位模式更好地对两种方法的患者进行分层?

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号